Updates in BCMA-directed therapies in multiple myeloma from ASH 2024

touchCONGRESS for touchHAEMATOLOGY

Multiple myeloma expert Prof. Katja Weisel summarizes key data for BCMA-targeted agents in multiple myeloma presented at the 2024 American Society of Hematology (ASH) Annual Meeting and Exposition. Prof. Weisel is then joined by fellow experts Dr Nisha Joseph and Prof. Roman Hájek to discuss the potential implications of the data for clinical practice. 

The experts

• Prof. Katja Weisel, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
• Dr Nisha Joseph, Emory University School of Medicine, Atlanta, GA, USA
• Prof. Roman Hájek, University Hospital Ostrava, Ostrava, Czech Republic

This touchPODCAST is for HCPs outside of the USA and UK.

This activity is funded by an independent medical education grant from GSK. 

This activity is provided by touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website: 

https://touchhaematologyime.org/bcma-directed-therapies-in-multiple-myeloma-ash2024/